Immuneel Therapeutics Raises ₹100 Crore Series B to Scale Disruptive Cancer Therapies Worldwide
What is the news?
Bengaluru-based clinical stage biotech startup Immuneel Therapeutics has successfully completed a Series B funding round, securing over ₹100 crore ($10.5 million). Co-founded by a powerhouse team of visionary Indian-origin leaders, biotech icon Kiran Mazumdar-Shaw, globally acclaimed oncologist and author Dr. Siddhartha Mukherjee, and venture capitalist Dr. Kush Parmar the company represents a prime example of Indian innovation scaling to capture global markets. The round saw participation from marquee institutional names including Singularity AMC, Rainmatter by Zerodha, Eight Roads Ventures, and F-Prime Capital.
Why is it interesting?
The fresh infusion of capital will be strategically deployed to expand Immuneel’s GMP manufacturing capabilities and accelerate the international footprint of Qartemi, which stands as India’s first approved commercial CAR-T cell therapy for Non-Hodgkin Lymphoma and leukemia. By lowering the financial barriers to advanced cell and gene therapies, the startup is setting a new international benchmark for affordable, bleeding-edge cancer treatment.
Looking beyond domestic borders, Immuneel is actively executing clinical co-development partnerships across Australia and Southeast Asia while setting its sights on broader expansions across the wider Asia-Pacific and Middle East corridors. This milestone underscores India’s evolving role not just as a technology backend, but as a critical, intellectual knowledge hub delivering breakthrough medical infrastructure to the entire world.
Read more: Immuneel Therapeutics raises over Rs 100 Cr in Series B